Skip to main content
. Author manuscript; available in PMC: 2008 Oct 1.
Published in final edited form as: Trends Cardiovasc Med. 2007 Oct;17(7):235–240. doi: 10.1016/j.tcm.2007.08.003

Figure 1.

Figure 1

Cardiac stem cells genetically modified to express nuclear-targeted AKT at one month post-infarction. Such genetic modifications by AKT may pave the road to enhancing cardiac progenitor cell proliferation and survival. Unmodified c-kit+ cardiac stem cells (red in overlay) under normal conditions (A) or genetically engineered to express nuclear-targeted AKT (myc-tagged; blue in overlay) together with bicistronic green fluorescent protein (GFP) in culture (B). Genetically modified cells as shown in (B) adoptively transferred to infarcted recipient mice persist and commit to the myocyte lineage after adoptive transfer to syngeneic mice (C and D) as identified by presence of GFP (green in overlay). Cardiac commitment is indicated by expression of tropomyosin (red in overlay) together with GFP (arrows). Blue in tissue sections represents nuclei.